Structure-Guided Optimization of Inhibitors of Acetyltransferase Eis from

Acetyltransferases / antagonists & inhibitors Bacterial Proteins / antagonists & inhibitors Drug Design Enzyme Inhibitors / chemistry Kanamycin Resistance / drug effects Microbial Sensitivity Tests Models, Molecular Molecular Structure Mycobacterium tuberculosis / drug effects Structure-Activity Relationship

Journal

ACS chemical biology
ISSN: 1554-8937
Titre abrégé: ACS Chem Biol
Pays: United States
ID NLM: 101282906

Informations de publication

Date de publication:
19 06 2020
Historique:
pubmed: 19 5 2020
medline: 27 4 2021
entrez: 19 5 2020
Statut: ppublish

Résumé

The enhanced intracellular survival (Eis) protein of

Identifiants

DOI: 10.1021/acschembio.0c00184 PMID: 32421305 PMC: PMC7385556
pubmed: 32421305
doi: 10.1021/acschembio.0c00184
pmc: PMC7385556
mid: NIHMS1596575
doi:

Substances chimiques

Bacterial Proteins 0
Enzyme Inhibitors 0
Acetyltransferases EC 2.3.1.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1581-1594

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI090048
Pays : United States

Références

J Biomol Screen. 1999;4(2):67-73
pubmed: 10838414
Mol Biosyst. 2012 Oct 30;8(12):3305-13
pubmed: 23090428
J Antimicrob Chemother. 2013 Apr;68(4):800-5
pubmed: 23233486
Biochemistry. 2012 Jun 19;51(24):4959-67
pubmed: 22646013
J Med Chem. 2016 Dec 8;59(23):10619-10628
pubmed: 27933949
ChemMedChem. 2012 Jan 2;7(1):73-7
pubmed: 21898832
ACS Infect Dis. 2017 Apr 14;3(4):302-309
pubmed: 28192916
Antimicrob Agents Chemother. 2013 Apr;57(4):1857-65
pubmed: 23380727
ACS Infect Dis. 2015 Jun 12;1(6):272-83
pubmed: 27622743
PLoS One. 2014 Apr 03;9(4):e92370
pubmed: 24699000
Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9804-8
pubmed: 21628583
Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20004-9
pubmed: 19906990
Biochemistry. 2015 May 26;54(20):3197-206
pubmed: 25928210
ACS Infect Dis. 2018 Jun 8;4(6):1030-1040
pubmed: 29601176
Antimicrob Agents Chemother. 2011 May;55(5):2032-41
pubmed: 21300839
Chembiochem. 2013 Nov 4;14(16):2127-35
pubmed: 24106131
ACS Chem Biol. 2016 Jun 17;11(6):1639-46
pubmed: 27010218
ACS Infect Dis. 2019 Oct 11;5(10):1772-1778
pubmed: 31433614
J Comput Chem. 2002 Apr 30;23(6):600-9
pubmed: 11939594
J Infect Dis. 2008 Apr 15;197(8):1079-81
pubmed: 18419525
Medchemcomm. 2018 Aug 17;9(9):1439-1456
pubmed: 30288219
ACS Med Chem Lett. 2016 Sep 15;7(12):1219-1221
pubmed: 27994767

Auteurs

Ankita Punetha (A)

Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536-0596, United States.

Huy X Ngo (HX)

Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536-0596, United States.

Selina Y L Holbrook (SYL)

Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536-0596, United States.

Keith D Green (KD)

Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536-0596, United States.

Melisa J Willby (MJ)

Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, United States.

Shilah A Bonnett (SA)

TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington 98102, United States.

Kyle Krieger (K)

TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington 98102, United States.
Center for Global Infectious Disease, Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, Washington 98145, United States.

Emily K Dennis (EK)

Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536-0596, United States.

James E Posey (JE)

Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, United States.

Tanya Parish (T)

TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington 98102, United States.
Center for Global Infectious Disease, Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, Washington 98145, United States.

Oleg V Tsodikov (OV)

Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536-0596, United States.
ORCID: 0000-0001-7094-4216

Sylvie Garneau-Tsodikova (S)

Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536-0596, United States.
ORCID: 0000-0002-7961-5555

Articles similaires

Atomic view of photosynthetic metabolite permeability pathways and confinement in synthetic carboxysome shells.

Daipayan Sarkar, Christopher Maffeo, Markus Sutter et al.
1.00
Photosynthesis Ribulose-Bisphosphate Carboxylase Carbon Dioxide Molecular Dynamics Simulation Cyanobacteria

Mathematical modeling of vancomycin release from Poly-L-Lactic Acid-Coated implants.

Papon Thamvasupong, Kwanchanok Viravaidya-Pasuwat
1.00
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation

Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases.

Arpine Sokratian, Ye Zhou, Meltem Tatli et al.
1.00
alpha-Synuclein Humans Animals Mice Lewy Body Disease

Menthol as an effective inhibitor of quorum sensing and biofilm formation in Candida albicans and Candida glabrata by targeting the transcriptional repressor TUP1.

Pouria Khodavandi, Maryam Miri Soogh, Fahimeh Alizadeh et al.
1.00
Biofilms Candida albicans Quorum Sensing Candida glabrata Menthol

Classifications MeSH

questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › Acyltransferases › Acetyltransferases › Structure-Guided Optimization of Inhibitors of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines bactériennes › Structure-Guided Optimization of Inhibitors of...
questionsmedicales.fr › Techniques d'investigation › Développement de médicament › Découverte de médicament › Conception de médicament › Structure-Guided Optimization of Inhibitors of...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Structure-Guided Optimization of Inhibitors of...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance microbienne aux médicaments › Résistance bactérienne aux médicaments › Résistance à la kanamycine › Structure-Guided Optimization of Inhibitors of...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › Structure-Guided Optimization of Inhibitors of...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles moléculaires › Structure-Guided Optimization of Inhibitors of...
questionsmedicales.fr › Phénomènes chimiques › Structure moléculaire › Structure-Guided Optimization of Inhibitors of...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Bâtonnets à Gram positif › Bâtonnets asporogènes à Gram positif › Bâtonnets asporogènes réguliers à Gram positif › Mycobacteriaceae › Mycobacterium › Mycobacterium tuberculosis › Structure-Guided Optimization of Inhibitors of...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Relation structure-activité › Structure-Guided Optimization of Inhibitors of...